Ambrisentan: A guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

被引：0
|
作者：
Behr J. [1 ]
Lyseng-Williamson K.A. [2 ]
机构：
[1] Division of Pulmonary Diseases, Department of Internal Medicine i, University of Munich, Munich
[2] Adis, A Wolters Kluwer Business, Auckland
来源：
Drugs & Therapy Perspectives | 2011年 / 27卷 / 1期
关键词：
Ambrisentan; therapeutic use; Endothelin-receptor-antagonists; Pulmonary-hypertension; treatment; Treatment-algorithms;
D O I：
10.2165/11205380-000000000-00000
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1 / 8
页数：7
相关论文
共 50 条
  • [31] Sildenafil - A review of its use in pulmonary arterial hypertension
    Croom, Katherine F.
    Curran, Monique P.
    DRUGS, 2008, 68 (03) : 383 - 397
  • [32] SildenafilA Review of its Use in Pulmonary Arterial Hypertension
    Katherine F. Croom
    Monique P. Curran
    Drugs, 2008, 68 : 383 - 397
  • [33] Sitaxentan (Thelin) therapy for patients with World Health Organization functional class II pulmonary arterial hypertension
    Galie, N.
    Benza, R.
    Burgess, G.
    Dilleen, M.
    Torbicki, A.
    EUROPEAN HEART JOURNAL, 2009, 30 : 259 - 259
  • [34] Agreeability Between Patient And Physician Assessment Of Who Functional Class And Visual Analog Scale In Pulmonary Arterial Hypertension
    Rabih, F.
    Sehgal, S.
    Chowdhury, A.
    Gadre, A.
    Highland, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Pulmonary Arterial Elastance Independently Predicts Exercise Capacity and NYHA Functional Class in Pulmonary Arterial Hypertension
    David, Sthuthi
    Bilchick, Kenneth C.
    Noutong, Steve
    Kwon, Younghoon
    Mehta, Nishaki M.
    Mihalek, Andrew
    Mubanga, Mwenya
    Breathett, Khadijah
    Mazimba, Sula
    CIRCULATION, 2019, 140
  • [36] TRIPLE COMBINATION THERAPY WITH MACITENTAN, RIOCIGUAT, AND SELEXIPAG IN A PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (FUNCTIONAL CLASS III)
    Proshkina, A. A.
    Tsareva, N. A.
    Nekludova, G., V
    Avdeev, S. N.
    KARDIOLOGIYA, 2021, 61 (10) : 104 - 107
  • [37] Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
    McGoon, Michael D.
    Frost, Adaani E.
    Oudiz, Ronald J.
    Badesch, David B.
    Galie, Nazzareno
    Olschewski, Horst
    McLaughlin, Vallerie V.
    Gerber, Michael J.
    Dufton, Chris
    Despain, Darrin J.
    Rubin, Lewis J.
    CHEST, 2009, 135 (01) : 122 - 129
  • [38] Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities
    McGoon, Michael D.
    Frost, Adaani E.
    Oudiz, Ronald J.
    Badesch, David B.
    Galie, Nazzareno
    Olschewski, Horst
    McLaughlin, Vallerie V.
    Rubin, Lewis J.
    CHEST, 2006, 130 (04) : 254S - 254S
  • [39] Use Of Pulmonary Arterial Hypertension Specific Therapy In Non-Who Group I Pulmonary Hypertension
    Shujaat, A.
    Bajwa, A.
    Bellardini, J.
    Jones, L. M.
    Usman, F.
    Cury, J. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [40] RIOCIGUAT FOR THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): RESPONDER ANALYSIS OF WHO FUNCTIONAL CLASS II PATIENTS FROM THE PATENT-1 STUDY
    E, Gruenig
    Sikirica, M.
    Curram, J.
    Davie, N.
    Ghofrani, H. A.
    VALUE IN HEALTH, 2013, 16 (07) : A513 - A513
12345